ArticleThe Journal of experimental medicine1998
Requirement of SH2-containing protein tyrosine phosphatases SHP-1 and SHP-2 for paired immunoglobulin-like receptor B (PIR-B)-mediated inhibitory signal.
Article in The Journal of experimental medicine, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 205 citations in OpenAlex.
- Persistent PirB cleavage drives Golgi-directed trafficking deficits underlying neurodegeneration.Translational neurodegeneration · 2026Article
- Trained Memory of Uterine Macrophages Improves Subsequent Pregnancy Outcomes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Angiopoietin-like protein 2 inhibits thrombus formation.Molecular and cellular biochemistry · 2025Article
- Article
- Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer.Antibody therapeutics · 2021Review
- HACS1 signaling adaptor protein recognizes a motif in the paired immunoglobulin receptor B cytoplasmic domain.Communications biology · 2020Article
- Immunosuppressive receptor LILRB1 acts as a potential regulator in hepatocellular carcinoma by integrating with SHP1.Cancer biomarkers : section A of Disease markers · 2020Article
- Angptl8 mediates food-driven resetting of hepatic circadian clock in mice.Nature communications · 2019Article
- Structure and flexibility of the extracellular region of the PirB receptor.The Journal of biological chemistry · 2019Article
- Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity.The Journal of clinical investigation · 2018Article
- Update on the role of endothelial cells in trauma.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2018Review
- CAMKs support development of acute myeloid leukemia.Journal of hematology & oncology · 2018Article
- Neuronal PirB Upregulated in Cerebral Ischemia Acts as an Attractive Theranostic Target for Ischemic Stroke.Journal of the American Heart Association · 2018Article
- Receptors That Inhibit Macrophage Activation: Mechanisms and Signals of Regulation and Tolerance.Journal of immunology research · 2018Review
- Shp1 function in myeloid cells.Journal of leukocyte biology · 2017Review
- The lectin Siglec-G inhibits dendritic cell cross-presentation by impairing MHC class I-peptide complex formation.Nature immunology · 2016Article
- Article
- Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?International journal of hematologic oncology · 2016Review
- Ikaros Is a Negative Regulator of B1 Cell Development and Function.The Journal of biological chemistry · 2016Article
- Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors.Cell cycle (Georgetown, Tex.) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paired immunoglobulin-like receptor B (PIR-B) (p91) molecule has been proposed to function as an inhibitory receptor in B cells and myeloid lineage cells. We demonstrate here that the cytoplasmic region of PIR-B is capable of inhibiting B cell activation. Mutational analysis of five cytoplasmic tyrosines indicate that tyrosine 771 in the motif VxYxxL plays the most crucial role in mediating the inhibitory signal. PIR-B-mediated inhibition was markedly reduced in the SH2-containing protein tyrosine phosphatases SHP-1 and SHP-2 double-deficient DT40 B cells, whereas this inhibition was unaffected in the inositol polyphosphate 5'-phosphatase SHIP-deficient cells. These data demonstrate that PIR-B can negatively regulate B cell receptor activation and that this PIR-B-mediated inhibition requires redundant functions of SHP-1 and SHP-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.